Latest News from ASCO in Action

Latest News from ASCO in Action

January 26, 2015

ASCO submitted comments to the U.S. Department of Health and Human Services (HHS) on the Centers for Medicare and Medicaid Services’ proposed rule, "Patient Protection and Affordable Care Act: HHS Notice of Benefit and Payment Parameters," which outlines provisions, modifications, and key payment parameters for the health insurance exchanges established by the Affordable Care Act.

January 23, 2015

On January 20, ASCO joined the American Medical Association (AMA) and several other professional organizations in sending a letter to the Department of Health and Human Services (HHS) voicing concern about the current trajectory and performance of the certification of electronic health records (EHR).

January 22, 2015

The House Energy and Commerce Committee's Health Subcommittee held a two-day hearing to discuss the Sustainable Growth Rate (SGR) formula, the system  used to set Medicare physician payments. The hearing focused on bipartisan ways to off-set the costs of SGR repeal and replace it with legislation to reform Medicare. Suggestions for paying for the off-sets ranged from using Overseas Contingency Operations funds, to increasing revenue, to moving the bill forward without any pay-fors, to reforming Medicare. The current cost of the bill is approximately $140 Billion.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.